Anders Jack 4

4 · Revolution Medicines, Inc. · Filed Jun 18, 2026

AI-generated summary of this filing

Updated Jun 18, 2026

Revolution Medicines (RVMD) CFO Anders Jack Sells 2,722 Shares

What Happened

Anders Jack, Chief Financial Officer of Revolution Medicines (RVMD), disposed of 2,722 shares on June 16, 2026. The shares were sold (S) in an open-market/private sale at a weighted average price of $156.12, generating proceeds of $424,956. The filing indicates the sale was made under a pre-established Rule 10b5-1 instruction to satisfy tax withholding related to RSU vesting.

Key Details

Transaction date: 2026-06-16; Form 4 filed: 2026-06-18 (timely).
Shares sold: 2,722; weighted average price: $156.12; price range across trades: $156.1105–$156.8251.
Proceeds reported: $424,956.
Reason/footnote: Sold pursuant to a Rule 10b5-1 instruction letter adopted May 31, 2023 to satisfy the reporting person’s tax withholding obligation upon RSU vesting (Footnote F1).
Filing notes it was executed in multiple trades and the filer will provide full trade-by-trade details on request (Footnote F2).
Holdings called out in the filing: includes 51,388 RSUs (F3) and 479 ESPP shares acquired May 31, 2026 (F4). The filing does not state a single total "owned after" figure.

Context

This sale was processed under a 10b5-1 plan for tax withholding related to RSUs, which is a common administrative transaction and does not necessarily indicate a change in insider sentiment. The filing appears timely (within the usual two-business-day Form 4 window).

Form 4

Period: 2026-06-16

Chief Financial Officer

Transactions

Sale
Common Stock
[F1][F2][F3][F4]
2026-06-16$156.12/sh−2,722$424,956→ 123,269 total

Footnotes (4)

[F1]Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units ("RSUs") after July 15, 2023.
[F2]This transaction was executed in multiple trades at prices ranging from $156.1105 to $156.8251. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
[F3]Includes 51,388 RSUs.
[F4]Includes 479 shares acquired under the Issuer's Employee Stock Purchase Plan on May 31, 2026.

Signature

/s/ Jack Anders|2026-06-18

1 file